S. A. Saïd

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Contemporary management of patients with atrial fibrillation in the Netherlands and Belgium: a report from the EORP-AF long-term general registry

G. Mairesse, J. Vijgen, G. Lip, 2021, Netherlands Heart Journal.

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Women treated with second‐generation zotarolimus‐eluting resolute stents and everolimus‐eluting xience V stents: insights from the gender‐stratified, randomized, controlled TWENTE trial

J. W. Louwerenburg, M. Stoel, F. H. Man, 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2014, The Lancet.

Outcomes of Fast-track Outpatient Clinic for Rhythm and Conduction Disorders: Focus on Postural Tachycardia Syndrome and Literature Review

Rene Bloo, S. A. Saïd, 2018 .

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2012, Journal of the American College of Cardiology.

Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.

J. W. Louwerenburg, M. Stoel, C. von Birgelen, 2013, Journal of the American College of Cardiology.

TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives

J. W. Louwerenburg, M. Stoel, F. H. Man, 2010, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

Dobutamine-Mediated Dynamic Left Ventricular Outflow Tract Obstruction Associated with Hypovolemic Shock: Value of Echocardiography and Importance of Early Recognition and Appropriate Volume Substitution

H. Woltjer, J. Fast, P. Danse, 2010 .

CORONARY INTERVENT IONS

J. W. Louwerenburg, M. Stoel, G. Linssen, 2014 .

Technical Feasibility and Design of a Shape Memory Alloy Support Device to Increase Ejection Fraction in Patients with Heart Failure

J. Paulusse, K. Aarnink, F. Halfwerk, 2019, Cardiovascular Engineering and Technology.

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents 2-Year Follow-Up of the Randomized TWENTE Trial

M. Stoel, G. Linssen, C. Birgelen, 2013 .